Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2025.0
(0.75%)
JPY 2025.0
(0.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.83 Billion JPY | -4.76% |
| 2022 | 10.33 Billion JPY | -9.84% |
| 2021 | 11.45 Billion JPY | 6.18% |
| 2020 | 10.79 Billion JPY | 13.79% |
| 2019 | 9.48 Billion JPY | 9.37% |
| 2018 | 8.67 Billion JPY | 6.82% |
| 2017 | 8.11 Billion JPY | 4.87% |
| 2016 | 7.74 Billion JPY | 7.12% |
| 2015 | 7.22 Billion JPY | 2.19% |
| 2014 | 7.07 Billion JPY | 18.08% |
| 2013 | 5.98 Billion JPY | 1.03% |
| 2012 | 5.92 Billion JPY | 4.77% |
| 2011 | 5.65 Billion JPY | 20.38% |
| 2010 | 4.7 Billion JPY | 27.15% |
| 2009 | 3.69 Billion JPY | 4.91% |
| 2008 | 3.52 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.25 Billion JPY | -11.56% |
| 2023 Q3 | 2.1 Billion JPY | -22.47% |
| 2023 Q4 | 2.54 Billion JPY | 20.86% |
| 2023 FY | 9.83 Billion JPY | -4.76% |
| 2023 Q2 | 2.71 Billion JPY | 9.7% |
| 2023 Q1 | 2.47 Billion JPY | 4.47% |
| 2022 Q3 | 2.54 Billion JPY | -3.56% |
| 2022 Q1 | 2.77 Billion JPY | 18.78% |
| 2022 Q2 | 2.63 Billion JPY | -5.0% |
| 2022 FY | 10.33 Billion JPY | -9.84% |
| 2022 Q4 | 2.36 Billion JPY | -6.92% |
| 2021 Q4 | 2.33 Billion JPY | -23.6% |
| 2021 Q1 | 3.27 Billion JPY | 70.11% |
| 2021 Q2 | 2.78 Billion JPY | -15.09% |
| 2021 FY | 11.45 Billion JPY | 6.18% |
| 2021 Q3 | 3.06 Billion JPY | 10.04% |
| 2020 Q2 | 2.7 Billion JPY | -13.82% |
| 2020 Q3 | 3.02 Billion JPY | 11.64% |
| 2020 Q4 | 1.92 Billion JPY | -36.23% |
| 2020 Q1 | 3.13 Billion JPY | 62.04% |
| 2020 FY | 10.79 Billion JPY | 13.79% |
| 2019 Q1 | 2.23 Billion JPY | 10.77% |
| 2019 FY | 9.48 Billion JPY | 9.37% |
| 2019 Q2 | 2.52 Billion JPY | 13.13% |
| 2019 Q3 | 2.78 Billion JPY | 10.42% |
| 2019 Q4 | 1.93 Billion JPY | -30.53% |
| 2018 Q3 | 2.25 Billion JPY | -2.65% |
| 2018 Q2 | 2.31 Billion JPY | 11.47% |
| 2018 Q4 | 2.01 Billion JPY | -10.71% |
| 2018 FY | 8.67 Billion JPY | 6.82% |
| 2018 Q1 | 2.08 Billion JPY | 7.13% |
| 2017 Q3 | 1.94 Billion JPY | -14.01% |
| 2017 Q1 | 1.97 Billion JPY | 7.61% |
| 2017 FY | 8.11 Billion JPY | 4.87% |
| 2017 Q4 | 1.94 Billion JPY | -0.08% |
| 2017 Q2 | 2.25 Billion JPY | 14.52% |
| 2016 Q1 | 1.82 Billion JPY | 0.04% |
| 2016 FY | 7.74 Billion JPY | 7.12% |
| 2016 Q4 | 1.83 Billion JPY | 0.01% |
| 2016 Q3 | 1.83 Billion JPY | -18.53% |
| 2016 Q2 | 2.25 Billion JPY | 23.46% |
| 2015 FY | 7.22 Billion JPY | 2.19% |
| 2015 Q1 | 1.92 Billion JPY | 2.28% |
| 2015 Q4 | 1.82 Billion JPY | 7.38% |
| 2015 Q3 | 1.69 Billion JPY | -4.63% |
| 2015 Q2 | 1.77 Billion JPY | -7.72% |
| 2014 Q4 | 1.88 Billion JPY | 13.18% |
| 2014 Q1 | 1.56 Billion JPY | -3.41% |
| 2014 Q2 | 1.95 Billion JPY | 24.72% |
| 2014 FY | 7.07 Billion JPY | 18.08% |
| 2014 Q3 | 1.66 Billion JPY | -14.77% |
| 2013 Q4 | 1.62 Billion JPY | 32.06% |
| 2013 FY | 5.98 Billion JPY | 1.03% |
| 2013 Q3 | 1.22 Billion JPY | -25.11% |
| 2013 Q1 | 1.49 Billion JPY | -3.79% |
| 2013 Q2 | 1.64 Billion JPY | 9.46% |
| 2012 Q3 | 1.25 Billion JPY | -18.97% |
| 2012 FY | 5.92 Billion JPY | 4.77% |
| 2012 Q2 | 1.55 Billion JPY | -0.23% |
| 2012 Q1 | 1.55 Billion JPY | 5.52% |
| 2012 Q4 | 1.55 Billion JPY | 23.68% |
| 2011 Q1 | 1.23 Billion JPY | 6.24% |
| 2011 FY | 5.65 Billion JPY | 20.38% |
| 2011 Q2 | 1.69 Billion JPY | 37.19% |
| 2011 Q3 | 1.24 Billion JPY | -26.68% |
| 2011 Q4 | 1.47 Billion JPY | 18.51% |
| 2010 Q1 | 992.77 Million JPY | 0.0% |
| 2010 Q3 | 1.2 Billion JPY | -10.14% |
| 2010 FY | 4.7 Billion JPY | 27.15% |
| 2010 Q4 | 1.16 Billion JPY | -3.14% |
| 2010 Q2 | 1.33 Billion JPY | 34.87% |
| 2009 Q2 | 1.03 Billion JPY | 0.0% |
| 2009 FY | 3.69 Billion JPY | 4.91% |
| 2008 FY | 3.52 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 79.818% |
| Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 99.55% |
| Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 94.766% |
| Shionogi & Co., Ltd. | 369.08 Billion JPY | 97.334% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | -177.871% |
| Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 89.858% |
| Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 74.258% |
| Eisai Co., Ltd. | 586.41 Billion JPY | 98.322% |
| Morishita Jintan Co., Ltd. | 5.99 Billion JPY | -64.038% |
| Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 87.541% |
| Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 81.104% |
| Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | 27.21% |
| Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | -27.152% |
| Tsumura & Co. | 68.81 Billion JPY | 85.703% |
| Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 73.651% |
| Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | 60.314% |
| Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 87.91% |
| Fuji Pharma Co., Ltd. | 16.51 Billion JPY | 40.424% |
| Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 80.393% |
| KYORIN Holdings, Inc. | 51.4 Billion JPY | 80.858% |
| Taiko Pharmaceutical Co.,Ltd. | 1.07 Billion JPY | -811.863% |
| SymBio Pharmaceuticals Limited | 4.41 Billion JPY | -123.055% |
| MedRx Co., Ltd | 26 Million JPY | -37742.308% |
| Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | -22.593% |
| Solasia Pharma K.K. | 337 Million JPY | -2819.585% |
| Modalis Therapeutics Corporation | -731 Thousand JPY | 1346064.432% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 30.66 Billion JPY | 67.915% |
| Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 81.887% |
| Cyfuse Biomedical K.K. | 37.74 Million JPY | -25967.719% |
| Toho Holdings Co., Ltd. | 112.98 Billion JPY | 91.292% |
| Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | -48.187% |